Breast Cancer News
In this section, access cutting-edge metastatic breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
New findings may pave the way for people with stage IV breast cancer in the bones to receive bone-strengthening treatment less often. These results could mean decreased risk of side effects.
To help doctors recommend treatment options based on research evidence and expert consensus, the American Society of Clinical Oncology released its first guidelines on treating metastatic HER2-positive breast cancer.
ASCO issued two clinical practice guidelines for this breast cancer type. One advises on systemic (whole body) therapies for HER2-positive breast cancer that has advanced outside of the breast, other than to the brain. The other recommends specifics on treating brain metastases.
Everolimus (Afinitor) and exemestane (Aromasin) taken at the same time may be an effective first-line treatment for hormone receptor-positive breast cancer that spread beyond the breast to other organs, after treatment with another aromatase inhibitor. This finding comes from a new analysis of data from the BOLERO-2 trial.
Research presented at the 2014 American Association for Cancer Research Annual Meeting suggests a new treatment pair may help double the time before estrogen receptor-positive, metastatic breast cancer grows or spreads.
The final analysis of survival data from the Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) trial is encouraging. Researchers confirmed what was seen as a trend in their initial secondary analysis: postmenopausal women with metastatic, hormone-positive breast cancer lived longer when given twice the past standard amount of fulvestrant (Faslodex).
Exercising often after breast cancer treatment ends may help women improve their quality of life over time, say researchers from the University of Illinois at Urbana-Champaign.
Women 65 and older received the same treatment benefit from the combination of pertuzumab (Perjeta), trastuzumab (Herceptin) and docetaxel (Taxotere) as women 64 and younger, a sub-analysis of CLEOPATRA trial data reveals.
Each December, medical experts and researchers from around the world meet at the 5-day San Antonio Breast Cancer Symposium to share the latest findings from breast cancer clinical trials. Read on for updates from the 2013 symposium, held December 10–14.
Women with lymphedema — swelling in the arm caused by the surgical removal of lymph nodes or by damage to the lymph nodes from radiation therapy for breast cancer — may perform upper-body strength training exercises with light and heavy weights, without worsening swelling or other lymphedema symptoms, Australian researchers say.
A study published in Psycho-Oncology suggests that the way a couple communicates about cancer-related concerns plays a role in worsening or improving symptoms of depression related to problems with sex and physical intimacy in women living with metastatic disease.